GLP-1 Medications for Weight Loss and Lymphedema: Benefits, Risks & Latest Research
New weight loss medications are completely changing how doctors treat metabolic health. Brands like Ozempic, Wegovy, and Mounjaro help…
-
-
Aleniglipron Phase 2 Obesity Trial Results
An experimental oral small molecule compound showed impressive results in a recent phase 2 clinical trial. The drug aleniglipron…
-
Oral GLP-1 Drugs Advance as Pharmaceutical Companies Race Toward Pill-Based Weight Loss Treatments
Multiple pharmaceutical companies are developing oral versions of GLP-1 receptor agonists. This class of drugs has changed the treatment…
-
GLP-1 Medications Linked to Misuse in Eating Disorders
A new study in JAMA Psychiatry highlights a concerning trend with GLP-1 receptor agonists. Researchers found that 32 percent…
-
Retatrutide Shows Sustained Weight Loss Benefits in Phase 3 TRIUMPH-1 Trial
The investigational triple hormone receptor agonist retatrutide targets GIP, GLP-1, and glucagon pathways. In the Phase 3 TRIUMPH-1 trial,…
-
GLP-1 Weight Loss Drugs Fuel a Surge in Cosmetic Procedures and Aesthetic Treatments
A new class of weight loss medications is changing what patients want from cosmetic clinics. These popular drugs help…
-
NHS Patients Face Record Drug Shortages, Warn Pharmacists and GPs
Pharmacists and doctors say there are serious shortages of medications. These supply issues affect painkillers, epilepsy treatments, and hormone…
-
Can New Oral Weight-Loss Drugs Help Women Manage Menopause Weight Gain?
Going through menopause is a major shift for a woman’s body. When estrogen levels drop, it changes how and…
-
Study: GLP-1 Drugs Save Adults $192K in Lifetime Medical Costs
A groundbreaking study from the National Bureau of Economic Research (NBER) reveals that lifetime use of GLP-1 obesity medications…
-
GLP-1 Drugs Show No Elevated Risk of Adverse Pregnancy Outcomes in First Trimester, Study Finds
A new medical study indicates that first-trimester GLP-1 receptor agonist exposure does not increase adverse pregnancy outcomes. Investigators published…
